{"product_id":"jbj-09-063-tfa-bhb20441121","title":"JBJ-09-063 TFA","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003ch2\u003eCompound Overview\u003c\/h2\u003e\n  \u003cp\u003e\u003cstrong\u003eJBJ-09-063 TFA\u003c\/strong\u003e is a research-grade small molecule supplied by TargetMol.\u003c\/p\u003e\n\n  \u003ch2\u003ePhysical Properties\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC33H30F4N4O5S\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e670.67 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eSolid\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eRoom Temperature (RT)\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n  \u003ch2\u003eBiological Activity\u003c\/h2\u003e\n  \u003cp\u003eJBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor, displaying IC50 values of 0.147 nM for EGFR L858R, 0.063 nM for EGFR L858R\/T790M, 0.083 nM for EGFR L858R\/T790M\/C797S, and 0.396 nM for EGFR L747S mutations. It effectively reduces phosphorylation of EGFR, Akt, and ERK1\/2, demonstrating efficacy in models sensitive and resistant to EGFR tyrosine kinase inhibitors (TKI). JBJ-09-063 TFA holds potential for research in EGFR-mutant lung cancer (1).\u003c\/p\u003e\n  \u003ch2\u003eSafety \u0026amp; Regulatory\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for therapeutic, diagnostic, or clinical use. Wear appropriate PPE and consult the Safety Data Sheet (SDS) prior to handling.\u003c\/p\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"TargetMol","offers":[{"title":"5 mg","offer_id":53327262384493,"sku":"T74561-5MG","price":0.0,"currency_code":"USD","in_stock":true},{"title":"50 mg","offer_id":53327385198957,"sku":"T74561-50MG","price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/jbj-09-063-tfa-bhb20441121","provider":"BioHippo","version":"1.0","type":"link"}